1.46
price up icon1.39%   0.02
after-market Handel nachbörslich: 1.48 0.02 +1.37%
loading
Schlusskurs vom Vortag:
$1.44
Offen:
$1.44
24-Stunden-Volumen:
1.83M
Relative Volume:
0.70
Marktkapitalisierung:
$530.56M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.825
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-3.95%
1M Leistung:
+26.96%
6M Leistung:
+175.47%
1J Leistung:
-18.44%
1-Tages-Spanne:
Value
$1.4215
$1.485
1-Wochen-Bereich:
Value
$1.40
$1.66
52-Wochen-Spanne:
Value
$0.2836
$2.175

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Firmenname
Lexicon Pharmaceuticals Inc
Name
Telefon
(281) 863-3000
Name
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Mitarbeiter
103
Name
Twitter
@LexPharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
1.46 541.46M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-05 Herabstufung Leerink Partners Outperform → Market Perform
2024-06-17 Eingeleitet H.C. Wainwright Buy
2024-04-30 Eingeleitet Leerink Partners Outperform
2023-03-07 Eingeleitet Jefferies Hold
2022-08-12 Eingeleitet Piper Sandler Overweight
2021-01-29 Hochstufung JP Morgan Underweight → Neutral
2021-01-29 Herabstufung Wedbush Outperform → Neutral
2020-12-08 Hochstufung Citigroup Neutral → Buy
2020-11-18 Hochstufung Gabelli & Co Hold → Buy
2019-12-11 Herabstufung Gabelli & Co Buy → Hold
2019-11-08 Herabstufung Citigroup Buy → Neutral
2019-09-11 Hochstufung Gabelli & Co Hold → Buy
2019-07-29 Herabstufung Stifel Buy → Hold
2019-03-25 Hochstufung Gabelli & Co Sell → Hold
2018-07-31 Bestätigt Stifel Buy
2018-02-23 Herabstufung Needham Buy → Hold
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-03-01 Bestätigt H.C. Wainwright Buy
2017-03-01 Bestätigt Wedbush Outperform
2016-10-07 Eingeleitet H.C. Wainwright Buy
2016-08-05 Bestätigt Wedbush Outperform
2016-08-02 Eingeleitet Citigroup Buy
2016-03-02 Bestätigt Wedbush Outperform
2015-11-09 Bestätigt Wedbush Outperform
2015-09-28 Hochstufung Gabelli & Co Sell → Hold
2015-09-18 Herabstufung Gabelli & Co Hold → Sell
2015-08-10 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
08:19 AM

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times

08:19 AM
pulisher
05:14 AM

Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com

05:14 AM
pulisher
02:50 AM

Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com

02:50 AM
pulisher
Oct 13, 2025

Is Lexicon Pharmaceuticals Inc. building a consolidation baseMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛

Oct 08, 2025
pulisher
Oct 06, 2025

Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st

Oct 02, 2025
pulisher
Sep 30, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat

Sep 30, 2025
pulisher
Sep 28, 2025

What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in

Sep 28, 2025
pulisher
Sep 26, 2025

Lexicon reports FDA's decision to extend review period for Zynquista - MSN

Sep 26, 2025
pulisher
Sep 24, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener

Sep 23, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus

Sep 22, 2025

Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Sullivan Diane E.
Director
May 13 '25
Option Exercise
0.00
36,810
0
36,810
SOBECKI CHRISTOPHER J
Director
May 13 '25
Option Exercise
0.00
36,810
0
203,865
BARKER SAM L
Director
May 13 '25
Option Exercise
0.00
36,810
0
124,459
Amouyal Philippe
Director
May 13 '25
Option Exercise
0.00
36,810
0
285,174
DEBBANE RAYMOND
Director
May 13 '25
Option Exercise
0.00
36,810
0
1,385,689
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):